A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients

Next Previous
Trial Profile

A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Epoprostenol (Primary) ; Epoprostenol
  • Indications Pulmonary hypertension
  • Focus Pharmacodynamics
  • Sponsors Aerogen

    • Most Recent Events

    • 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
    • 08 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 24 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top